Quantum Genomics Logo

Quantum Genomics

Biopharma developing cardiovascular treatments, now in judicial liquidation.

ALQGC | PA

Overview

Corporate Details

ISIN(s):
FR0010783837 (+4 more)
LEI:
969500TFCD8K9RPM9K97
Country:
France
Address:
6 RUE CAMBACERES, 75008 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quantum Genomics is a biopharmaceutical company focused on developing treatments for unmet medical needs, particularly in cardiovascular diseases such as hypertension and heart failure. The company's research was centered on a novel therapeutic approach involving Brain Aminopeptidase A Inhibition (BAPAI), with its lead drug candidate being firibastat. In early 2024, Quantum Genomics acquired the company Exactcure. However, recent developments indicate that the company has subsequently filed for judicial liquidation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 18:00
Post-Annual General Meeting Information
Report de l'Assemblée Générale Mixte du 30/06/2025
French 116.4 KB
2025-04-30 20:00
Earnings Release
Quantum Genomics publishes its 2024 annual financial statements and announces a…
English 206.5 KB
2025-04-30 20:00
Delisting Announcement
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de li…
French 254.0 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics fait un point sur sa situation
French 688.8 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics provides an update on its situation
English 626.0 KB
2024-10-29 18:00
Earnings Release
Quantum Genomics publie ses résultats du 1er semestre 2024 et annonce la nomina…
French 241.2 KB
2024-09-27 08:00
Legal Proceedings Report
Quantum Genomics sécurise un financement avec le fonds Akkadian Partners Fund e…
French 74.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics reviewed its financial situation and announced that it has fil…
English 175.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics fait un point sur sa situation financière et annonce qu'elle a…
French 150.0 KB
2024-07-03 13:00
Capital/Financing Update
BILAN SEMESTRIEL S1 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE…
French 275.3 KB
2024-03-13 18:00
Business and Financial Review
Quantum Genomics publie ses résultats de l'exercice 2023. Le rapprochement avec…
French 193.8 KB
2024-03-13 18:00
Earnings Release
Quantum Genomics publishes its results for the 2023 financial year. The merger …
English 166.3 KB
2024-01-10 16:35
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2024-01-10 16:30
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2023-12-14 18:05
Regulatory News Service
Quantum Genomics enters into exclusive negotiations with ExactCure
English 286.1 KB

Automate Your Workflow. Get a real-time feed of all Quantum Genomics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Quantum Genomics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.